Pulmatrix, Inc. (PULM)
NASDAQ: PULM · Real-Time Price · USD
2.079
-0.051 (-2.40%)
Nov 4, 2024, 4:00 PM EST - Market closed
Pulmatrix Employees
Pulmatrix had 22 employees as of December 31, 2023. The number of employees decreased by 7 or -24.14% compared to the previous year.
Employees
22
Change (1Y)
-7
Growth (1Y)
-24.14%
Revenue / Employee
$517,818
Profits / Employee
-$492,864
Market Cap
7.59M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Vaccinex | 40 |
NeuroMetrix | 26 |
BioCardia | 20 |
Plus Therapeutics | 20 |
ABVC BioPharma | 19 |
Edesa Biotech | 16 |
Soligenix | 15 |
Cardio Diagnostics Holdings | 9 |
PULM News
- 2 months ago - Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 5 months ago - Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation - PRNewsWire
- 6 months ago - Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) - PRNewsWire
- 6 months ago - Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 7 months ago - Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update - PRNewsWire
- 10 months ago - Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives - PRNewsWire
- 1 year ago - Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update - PRNewsWire
- 1 year ago - Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine - PRNewsWire